← Back to Clinical Trials
Recruiting NCT04925427

NCT04925427 Reducing Opioid Mortality in Illinois

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04925427
Status Recruiting
Phase
Sponsor University of Chicago
Condition Opioid Use
Study Type INTERVENTIONAL
Enrollment 1,500 participants
Start Date 2021-08-10
Primary Completion 2026-08-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Case Management and Peer RecoveryNaloxone-Only

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,500 participants in total. It began in 2021-08-10 with a primary completion date of 2026-08-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Reducing Opioid Mortality in Illinois (ROMI) is 5-year research study led by the University of Chicago in partnership with the University of Illinois at Chicago's (UIC) Community Outreach Intervention Projects (COIP), the Illinois Criminal Justice Information Authority (ICJIA) and the American Institutes for Research (AIR). ROMI aims to understand and test strategies for linking individuals with a history of opioid use disorder who are released from Illinois jails and prisons to substance use treatment. ROMI is one of twelve grants awarded by the National Institutes of Health (NIH) as part of the Justice Community Opioid Innovation Network (JCOIN) to support research on quality addiction treatment for opioid use disorder in criminal justice settings nationwide.

Eligibility Criteria

Inclusion Criteria: * Participants must be at least 18 years old * Reside in designated research site county or zip code * Satisfy criteria for likely OUD based upon nonmedical use of prescription opioids, heroin, or synthetic opioids. Exclusion Criteria: * Participants experiencing cognitive impairments that preclude informed consent. * Reside out of the service area. * Prior enrollment in a parallel JCOIN study.

Contact & Investigator

Central Contact

Harold Pollack, PhD

✉ haroldp@uchicago.edu

📞 773-834-4292

Principal Investigator

Harold Pollack, PhD

PRINCIPAL INVESTIGATOR

University of Chicago

Frequently Asked Questions

Who can join the NCT04925427 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04925427 currently recruiting?

Yes, NCT04925427 is actively recruiting participants. Contact the research team at haroldp@uchicago.edu for enrollment information.

Where is the NCT04925427 trial being conducted?

This trial is being conducted at Chicago, United States, Murphysboro, United States, Ottawa, United States, Springfield, United States and 1 additional location.

Who is sponsoring the NCT04925427 clinical trial?

NCT04925427 is sponsored by University of Chicago. The principal investigator is Harold Pollack, PhD at University of Chicago. The trial plans to enroll 1,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology